1619931-27-9
1619931-27-9
Chemical Structure
Seralutinib
Synonym(s): GB002; PK10571
- CAS No.: 1619931-27-9
- Formula:C27H27N5O3
- Molecular Weight:469.53
IUPAC Name: (S)-N-(3-(1-((6-(3,4-dimethoxyphenyl)pyrazin-2-yl)amino)ethyl)phenyl)-5-methylnicotinamide
InChIKey: JHJNPOSPVGRIAN-SFHVURJKSA-N
SMILES: O=C(C1=CC(C)=CN=C1)NC2=CC=CC([C@@H](NC3=NC(C4=CC=C(OC)C(OC)=C4)=CN=C3)C)=C2
Biological Activity: Seralutinib (GB002) is an inhaled PDGFRα and PDGFRβ inhibitor. Seralutinib also targets to CSF1R and c-KIT with IC50s of 8 nM and 14 nM, respectively. Seralutinib (GB002) is used in the study for pulmonary arterial hypertension[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Seralutinib | 99.94% | Seralutinib (GB002) is an inhaled PDGFRα and PDGFRβ inhibitor. Seralutinib also targets to CSF1R and c-KIT with IC50s of 8 nM and 14 nM, respectively. Seralutinib (GB002) is used in the study for pulmonary arterial hypertension. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Seralutinib (Standard) | ≥98% | Seralutinib (Standard) is the analytical standard of Seralutinib (HY-109190). This product is intended for research and analytical applications. Seralutinib (GB002) is an inhaled PDGFRα and PDGFRβ inhibitor. Seralutinib also targets to CSF1R and c-KiT with IC50s of 8 nM and 14 nM, respectively. Seralutinib (GB002) is used in the study for pulmonary arterial hypertension. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Robert P. Frantz1, et.al. Phase 2 Clinical Study to Evaluate the Efficacy and Safety of Inhaled GB002 (Seralutinib) for the Treatment of World Health Organization Group 1 Pulmonary Arterial Hypertension
- [2]. Anna Galkin, et al. Abstract 11102: Gb002, A Novel Inhaled Pdgfr Kinase Inhibitor, Demonstrates Efficacy in the Su5416 Hypoxia Rat Model of Pulmonary Arterial Hypertension (pah). Circulation. 2019;140:A11102.
